首页   >  
MAPK Pathway
  >  
Raf
  >   Encorafenib
Encorafenib 结构式

Encorafenib

参考资料 仅供科学研究,不可用于个人用途。
货号 :BCP44104CAS号 :1269440-29-0纯度:98%
全国免运费!免费咨询:400-099-8200 或 手机联系:13472751340
即时询价 ×

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • 基本信息与产品描述
CAS号 1269440-29-0 货号 BCP44104
中文名 Encorafenib
英文名 Encorafenib
中文别名
英文别名 LGX818; LGX-818; LGX 818;
SMILES CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC
化学名称
分子式 C22H27ClFN7O4S 分子量 540.01
纯度 98% 配送 惯例下常温包邮
产品描述 Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.
  • 技术资料和支持
在购买和使用瀚香生物产品的过程中,您遇到的任何问题,都可以咨询我们的免费热线:400-099-8200,或者和我们的客服 。 我们竭诚解决您的一切疑惑,保证您的舒心顺畅。

相关产品推荐

查看更多 >

Tags:Encorafenib 供应商,Encorafenib 购买,Encorafenib 生产,Encorafenib 批量,Encorafenib 供应,Encorafenib 订购,Encorafenib 采购

2853530910